Form 8-K - Current report:
SEC Accession No. 0001104659-25-092162
Filing Date
2025-09-22
Accepted
2025-09-22 16:39:10
Documents
14
Period of Report
2025-09-22
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mxct-20250922x8k.htm   iXBRL 8-K 46975
2 EX-99.1 mxct-20250922xex99d1.htm EX-99.1 10466
3 GRAPHIC mxct-20250922xex99d1001.jpg GRAPHIC 5862
  Complete submission text file 0001104659-25-092162.txt   188290

Data Files

Seq Description Document Type Size
4 EX-101.SCH mxct-20250922.xsd EX-101.SCH 3417
5 EX-101.LAB mxct-20250922_lab.xml EX-101.LAB 16578
6 EX-101.PRE mxct-20250922_pre.xml EX-101.PRE 10717
16 EXTRACTED XBRL INSTANCE DOCUMENT mxct-20250922x8k_htm.xml XML 5020
Mailing Address 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850
Business Address 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 301-517-5556
MAXCYTE, INC. (Filer) CIK: 0001287098 (see all company filings)

EIN.: 522210438 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40674 | Film No.: 251330552
SIC: 8731 Services-Commercial Physical & Biological Research
(CF Office: 08 Industrial Applications and Services)